Stock Detail
CEPHALON INC
Biotechnology
CEPH @ Yahoo Finance | CEPH Option @ Yahoo Finance
Last Day's Data
| Current Price | High | Value Change | Percent Change | Dividend | Previous Close |
|---|---|---|---|---|---|
| $56.29 | $56.74 | $-0.58 | -1.02% | 0.00 | $56.87 |
| Opening Price | Low | Volume | Market Cap | Average Volume | P/E |
| $56.62 | $55.77 | 1.48M | 4.27B | 1.43M | 10.68 |
Pivot Table
| R2 | R1 | Pivot | S1 | S2 |
| 57.24 | 56.77 | 56.27 | 55.80 | 55.30 |
Stock Profile
Cephalon, Inc., a biopharmaceutical company, engages in the discovery, development, and marketing of products to treat sleep disorders, neurological disorders, cancer, and pain primarily in the United States. The company, through its wholly-owned subsidiary, CIMA LABS INC., also develops and manufactures orally disintegrating tablets using proprietary technologies. It markets three proprietary products, including Provigil for treating of excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome and shift work sleep disorder; Actiq for treating pain in opiod-tolerant cancer patients; and Gabitril, which is used as an adjunct therapy for treatment of partial seizures associated with epilepsy. The company sells its products primarily in North America and Europe. Cephalon has an agreement with Bio3 Research and Creabilis to develop K 252a-based products as topical therapies for psoriasis and for the treatment and prevention of restenosis. The company was founded by Frank Baldino, Jr. and is headquartered in West Chester, Pennsylvania.